S1148
Clinical - Urology
ESTRO 2026
Conclusion: These results complement data from randomized controlled trials, offering a pragmatic perspective on adverse side effect patterns in an unselected, routinely treated MHRT cohort. PROs showed to possess a clinically relevant discriminatory value underscoring their potential to guide personalized treatments and follow-up and inform AI-driven outcome prediction models. References: 1 Murthy V, et al. Prostate-only versus whole-pelvic radiation therapy in high-risk and very high-risk prostate cancer (POP-RT): outcomes from phase III randomized controlled trial. J Clin Oncol. 2021;39(11):1234-1242. doi:10.1200/JCO.20.032822 Murthy V, et al. Late toxicity and quality of life with prostate only or whole pelvic radiation therapy in high risk prostate cancer (POP-RT): a randomised trial. Radiother Oncol. 2020;145:71-80. doi:10.1016/j.radonc.2019.12.00 Keywords: outcomes, prostate cancer, lymph node irradiation limited systemic therapy for the treatment of low- volume pelvic-only metastatic hormone-sensitive prostate cancer Kieran Palmer 1,2 , Tylan Lucas 1 , Charmaine Toh 2 , Nishanthi Senthivel 3 , Shahin Ghezelayagh 3 , Alex Pawsey 4 , Pavlos Christodoulou 4 , Nicola O'Neill 2 , Paula Wells 4 , Karen Tipples 4 , Stephen Morris 3 , Sonia Mansukhani 5 , Amy Clifford 1 , Sarah Needleman 1 , Matthew Fittall 2 , Mark Prentice 1 1 Clinical Oncology, Royal Free Hospital, London, United Kingdom. 2 Clinical Oncology, University College London Hospital, London, United Kingdom. 3 Clinical Oncology, Guys Hospital, London, United Kingdom. 4 Clinical Oncology, St Bartholomew's Hospital, London, United Kingdom. 5 Medical Oncology, Royal Free Hospital, London, United Kingdom Purpose/Objective: Localised prostate radiotherapy has been shown to improve overall survival (OS) in men with low-volume metastatic hormone-sensitive prostate cancer (mHSPC) receiving life-long systemic therapy. This study evaluated oncological outcomes in patients with low-volume pelvic oligometastatic mHSPC (po-mHSPC) treated with pelvic all-site radical radiotherapy, encompassing the prostate/prostate bed, pelvic lymph nodes, and bone metastases. Material/Methods: We conducted a multi-centre retrospective Digital Poster 614 Pelvic radiotherapy and time-
Made with FlippingBook - Share PDF online